Related Experiment Videos
In vivo activity of cefbuperazone (T-1982) against various experimental infections in mice
Abstract:
The protective activity of cefbuperazone (T-1982) was compared with those of latamoxef, cefotaxime, and cefmetazole against intraperitoneal and urinary tract infections in mice. In both tests, cefbuperazone manifested a higher activity than the other cephems against infections with Escherichia coli and Klebsiella pneumoniae. Cefbuperazone also showed a comparatively high degree of prophylactic effect; this activity was observed even when given 4 hours before bacterial challenge. The good in vivo activity of cefbuperazone could not be explained by the differences between the antibiotics on the basis of the serum levels and vitro activity. Mice, treated with cefbuperazone, showed a statistically significant prolongation of survival time against intraperitoneal challenge with Candida albicans, but not when treated with the other cephems. This finding suggests that the host defense mechanisms stimulated by cefbuperazone may contribute to the good in vivo activity of this antibiotic.
Insights
Cefbuperazone demonstrated superior protective activity against bacterial infections in mice compared to other cephalosporins. Its effectiveness, even when administered prophylactically, suggests it may enhance host defense mechanisms.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance necessitates the development of novel therapeutic agents.
- Cephalosporins are a class of beta-lactam antibiotics widely used to treat bacterial infections.
Purpose of the Study:
- To evaluate the in vivo protective activity of cefbuperazone against bacterial infections.
- To compare the efficacy of cefbuperazone with other cephalosporins in murine models.
Main Methods:
- Murine models of intraperitoneal and urinary tract infections were utilized.
- Infections were induced with Escherichia coli, Klebsiella pneumoniae, and Candida albicans.
- Antibiotic efficacy was assessed based on survival rates and time to mortality.
Main Results:
- Cefbuperazone exhibited higher activity than latamoxef, cefotaxime, and cefmetazole against E. coli and K. pneumoniae infections.
- A significant prophylactic effect was observed with cefbuperazone, even when administered 4 hours prior to challenge.
- Cefbuperazone treatment prolonged survival in mice challenged with Candida albicans, unlike other cephalosporins.
Conclusions:
- Cefbuperazone demonstrates potent in vivo antibacterial activity, exceeding that of comparator cephalosporins.
- The antibiotic's prophylactic efficacy suggests a role beyond direct antimicrobial action.
- Enhanced host defense mechanisms may contribute to cefbuperazone's overall therapeutic effectiveness.